keyword
MENU ▼
Read by QxMD icon Read
search

anthracycline cardio

keyword
https://www.readbyqxmd.com/read/29217664/incidence-diagnosis-and-management-of-qt-prolongation-induced-by-cancer-therapies-a-systematic-review
#1
REVIEW
Andreu Porta-Sánchez, Cameron Gilbert, Danna Spears, Eitan Amir, Joyce Chan, Kumaraswamy Nanthakumar, Paaladinesh Thavendiranathan
BACKGROUND: The cardiovascular complications of cancer therapeutics are the focus of the burgeoning field of cardio-oncology. A common challenge in this field is the impact of cancer drugs on cardiac repolarization (ie, QT prolongation) and the potential risk for the life-threatening arrhythmia torsades de pointes. Although QT prolongation is not a perfect marker of arrhythmia risk, this has become a primary safety metric among oncologists. Cardiologists caring for patients receiving cancer treatment should become familiar with the drugs associated with QT prolongation, its incidence, and appropriate management strategies to provide meaningful consultation in this complex clinical scenario...
December 7, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28934410/approach-to-cardio-oncologic-patients-with-special-focus-on-patients-with-cardiac-implantable-electronic-devices-planned-for-radiotherapy-results-of-the-european-heart-rhythm-association-survey
#2
Radoslaw Lenarczyk, Tatjana S Potpara, Kristina H Haugaa, Jean-Claude Deharo, Antonio Hernandez-Madrid, Maria Del Carmen Exposito Pineda, Marek Kiliszek, Nikolaos Dagres
The aim of this European Heart Rhythm Association (EHRA) survey was to evaluate clinical practice regarding cardio-oncologic patients, with special focus on patients with cardiac implantable electronic devices (CIEDs) planned for anticancer radiotherapy (RT), among members of the EHRA electrophysiology research network. Of the 36 responding centres, 89% managed patients who were diagnosed or treated oncologically, and this diagnosis affected 1-5% of cardiovascular patients in majority of centres (57%). The main side effects of anticancer therapy in patients treated by cardiologists were thromboembolic complications and left ventricular dysfunction (both reported as 'frequent' by 43% of the centres)...
September 1, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28887671/histamine-2-receptor-antagonism-elicits-protection-against-doxorubicin-induced-cardiotoxicity-in-rodent-model
#3
Sundar Kumar Kondru, Ajay Godwin Potnuri, Lingesh Allakonda, Prasad Konduri
Doxorubicin (DOX), an anthracycline-based antibiotic, is regularly used in the management of carcinomas, and haematological malignancies have been downplayed in chemotherapy because of its ability to induce dilated cardiomyopathy (DCM). Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects. Redox imbalance and reactive oxygen species generation plays major role in DOX-induced cardiotoxicity. Histamine, known to mediate various cardiovascular effects, but nevertheless the role of histamine or its receptors in DOX-induced DCM is remained obscure...
September 8, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28781723/developing-a-comprehensive-cardio-oncology-program-at-a-cancer-institute-the-moffitt-cancer-center-experience
#4
REVIEW
Michael G Fradley, Allen C Brown, Bernadette Shields, Federico Viganego, Rongras Damrongwatanasuk, Aarti A Patel, Gregory Hartlage, Natalee Roper, Julie Jaunese, Larry Roy, Roohi Ismail-Khan
Cardio-oncology is a multidisciplinary field focusing on the management and prevention of cardiovascular complications in cancer patients and survivors. While the initial focus of this specialty was on heart failure associated with anthracycline use, novel anticancer agents are increasingly utilized and are associated with many other cardiotoxicities including hypertension, arrhythmias and vascular disease. Since its inception, the field has developed at a rapid pace with the establishment of programs at many major academic institutions and community practices...
June 14, 2017: Oncology Reviews
https://www.readbyqxmd.com/read/28774277/novel-approaches-to-the-prediction-diagnosis-and-treatment-of-cardiac-late-effects-in-survivors-of-childhood-cancer-a-multi-centre-observational-study
#5
Amy Skitch, Seema Mital, Luc Mertens, Peter Liu, Paul Kantor, Lars Grosse-Wortmann, Cedric Manlhiot, Mark Greenberg, Paul C Nathan
BACKGROUND: Anthracycline-induced cardiac toxicity is a cause of significant morbidity and early mortality in survivors of childhood cancer. Current strategies for predicting which children are at greatest risk for toxicity are imperfect and diagnosis of cardiac injury is usually made relatively late in the natural history of the disease. This study aims to identify genomic, biomarker and imaging parameters that can be used as predictors of risk or aid in the early diagnosis of cardiotoxicity...
August 3, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28759384/cardiotoxic-effects-of-anthracycline-based-therapy-what-is-the-evidence-and-what-are-the-potential-harms
#6
REVIEW
Bennett E Levis, Phillip F Binkley, Charles L Shapiro
Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-based guidelines exist for the surveillance and prevention of chemotherapy-induced cardiotoxicity in adult survivors of breast cancer who have had limited previous doses of anthracyclines (ie, total cumulative dose 240 mg/m2), or limited-dose anthracyclines followed by trastuzumab-based regimens. Nonetheless, some national and international cardio-oncology and cardiac-imaging organisations recommend increased cardiac surveillance during or after treatment, measurement of cardiac biomarkers and other surrogate endpoints, and in some cases initiation of cardioprotective drug therapy in asymptomatic women...
August 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28725323/the-elevation-of-cardio-ankle-vascular-index-in-a-patient-with-malignant-lymphoma-treated-with-a-combination-therapy-of-rituximab-and-cyclophosphamide-doxorubicin-vincristine-and-prednisolone
#7
Naomi Shimizu, Noriko Ban, Yasuhiro Watanabe, Asami Rikitake, Rena Watanabe, Sho Tanaka, Yuta Sato, Haruki Imamura, Hidetoshi Kawana, Takashi Yamaguchi, Atsuhito Saiki, Ichiro Tatsuno, Kohji Shirai
An increased risk of arteriosclerosis has been noted in cancer survivors. Currently, there are only a few reports available that consider the risk of arteriosclerosis in patients treated with chemotherapy. Patients with an advanced stage B-cell malignant lymphoma are typically treated with a combination therapy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Complications such as diabetes mellitus (DM), hyperlipidemia (HL), and osteoporosis due to prednisolone and cardiotoxicity due to anthracyclines are well known...
August 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28713868/21st-century-cardio-oncology-identifying-cardiac-safety-signals-in-the-era-of-personalized-medicine
#8
Calvin Chen Sheng, Laleh Amiri-Kordestani, Todd Palmby, Thomas Force, Charles C Hong, Joseph C Wu, Kevin Croce, Geoffrey Kim, Javid Moslehi
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than traditional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular (CV) complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies...
August 2016: JACC. Basic to Translational Science
https://www.readbyqxmd.com/read/28679288/chemotherapy-induced-cardiotoxicity-in-children
#9
REVIEW
Neha Bansal, Shahnawaz Amdani, Emma R Lipshultz, Steven E Lipshultz
With advances in clinical oncology, the burden of morbidity and mortality for cancer survivors due to the cardiac side effects of the chemotherapy is steadily increasing. Treatment-related cardiac damage is progressive and often irreversible. Primary prevention of cardiotoxicity during treatment is possible with strategies like limiting the cumulative anthracycline dose, the use of anthracycline structural analogs, and especially cardioprotective agents. Areas covered: This review covers the various cardiotoxic chemotherapeutic agents, the pathophysiology of cardiotoxicity due to anthracyclines, and the clinical and subclinical presentations and progression of childhood anthracycline cardiotoxicity...
August 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28660778/cardio-oncology-cardiovascular-complications-of-cancer-therapy
#10
Robert J Henning, Raymond D Harbison
This paper focuses on three classes of commonly used anticancer drugs, which can cause cardiotoxicity: anthracyclines, monoclonal antibodies exemplified by trastuzumab and tyrosine kinase inhibitors. Anthracyclines can induce cardiomyocyte necrosis and fibrosis. Trastuzumab can cause cardiac stunning. The tyrosine kinase inhibitors can increase systemic arterial pressure and impair myocyte contractility. In addition, radiation therapy to the mediastinum or left chest can exacerbate the cardiotoxicity of these anticancer drugs and can also cause accelerated atherosclerosis, myocardial infarction, heart failure and arrhythmias...
July 2017: Future Cardiology
https://www.readbyqxmd.com/read/28505345/cardio-oncology-a-multidisciplinary-approach-for-detection-prevention-and-management-of-cardiac-dysfunction-in-cancer-patients
#11
Kazuko Tajiri, Kazutaka Aonuma, Ikuo Sekine
Cardiac dysfunction that develops during or after completion of cancer therapy is a growing health concern that should be addressed in a multidisciplinary setting. Cardio-oncology is a new discipline that focuses on screening, monitoring and treating cardiovascular disease during and after cancer treatment. A baseline cardiovascular risk assessment is essential. For high-risk patients, a tailored and detailed plan for cardiovascular management throughout treatment and beyond should also be established. Anthracycline and/or trastuzumab-containing chemotherapy and chest-directed radiation therapy are well known cardiotoxic cancer therapies...
August 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28474324/role-of-imaging-in-cardio-oncology
#12
REVIEW
Erick Avelar, Caitlin R Strickland, Guido Rosito
Recent advances in cancer treatment and research have greatly improved survival rates for patients with cancer. However, many of these cancer survivors are developing cardiac disease-most commonly heart failure as a result of this treatment. Certain chemotherapeutic agents, including anthracyclines and trastuzumab, have been linked to cardiotoxicity-induced cardiomyopathy in cancer patients. It has been reported as early as during infusion and as late as several years following treatment. Radiation therapy, particularly to the left breast, has also been linked to cardiac disease...
June 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28365180/practices-in-management-of-cancer-treatment-related-cardiovascular-toxicity-a-cardio-oncology-survey
#13
Ludovic Jovenaux, Jennifer Cautela, Noemie Resseguier, Michele Pibarot, Myriam Taouqi, Morgane Orabona, Johan Pinto, Michael Peyrol, Jeremie Barraud, Marc Laine, Laurent Bonello, Franck Paganelli, Fabrice Barlesi, Franck Thuny
BACKGROUND: Cardiovascular toxicity has become a challenging issue during cancer therapy. Nonetheless, there is a lack of consensual guidelines for their management. We aimed to determine the current practices of oncologists regarding cardiovascular toxicity related to anthracyclines, trastuzumab and angiogenic inhibitors and to gather their opinions on the development of cardio-oncology programs. METHODS: A cross-sectional declarative study was submitted to French oncologists in the form of an individual, structured questionnaire...
March 21, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28336372/doxorubicin-targets-multiple-players-a-new-view-of-an-old-problem
#14
REVIEW
Donato Cappetta, Francesca Rossi, Elena Piegari, Federico Quaini, Liberato Berrino, Konrad Urbanek, Antonella De Angelis
Anthracycline cardiotoxicity remains a serious problem in paediatric and adult cancer survivors, and the advancement of cardio-oncology is a necessary step for an effective care of the patients that experience adverse cardiovascular effects. In this review, we discuss the multiple instruments used by clinicians that constitute the current strategies for primary and secondary prevention aiming at contrasting the onset of early and late doxorubicin-induced cardiotoxic events. The importance of early detection of cardiotoxicity and the following pharmacological therapy has been acknowledged with the emphasis put on impaired diastolic function, an increasingly recognized precocious sign of doxorubicin cardiotoxicity with an emerging scientific and clinical interest...
March 20, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28315122/cardio-oncology-the-nuclear-option
#15
REVIEW
Jorge A Alvarez, Raymond R Russell
PURPOSE OF REVIEW: Cardio-oncology focuses increased effort to decrease cancer treatment-related cardiotoxicity while continuing to improve outcomes. We sought to synthesize the latest in nuclear cardiology as it pertains to the assessment of left ventricular function in preventative guidelines and comparison to other modalities, novel molecular markers of pre-clinical cardiotoxicity, and its role in cardiac amyloid diagnosis. RECENT FINDINGS: Planar ERNA (equilibrium radionuclide angiocardiography) provides a reliable and proven means of monitoring and preventing anthracycline cardiotoxicity, and SPECT ERNA using solid-state gamma cameras may provide reproducible assessments of left ventricular function with reduced radiation exposure...
April 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28285949/considerations-in-cardio-oncology-multiple-mobile-left-sided-cardiac-thrombi-in-chemotherapy-induced-cardiomyopathy
#16
Toshinori Minamishima, Kenichi Matsushita, Hiromu Morikubo, Aoi Isaka, Noriko Matsushita, Hidehito Endo, Hiroshi Kubota, Konomi Sakata, Toru Satoh, Hideaki Yoshino
With advances in cancer chemotherapy, the importance of the new clinical discipline of cardio-oncology, which is concerned with the cardiac effects of chemotherapy, is increasing. Herein we describe the case of a 48-year-old woman with a history of breast cancer who presented with symptoms of heart failure due to chemotherapy-induced cardiomyopathy. Treatment for the patient's breast cancer had included surgery and chemotherapy with anthracyclines and trastuzumab. Echocardiography revealed multiple mobile thrombi in the left ventricle and atrium...
March 10, 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28268088/acute-decompensated-heart-failure-as-a-reason-of-premature-chemotherapy-discontinuation-may-be-independent-of-a-lifetime-doxorubicin-dose-in-lymphoma-patients-with-cardiovascular-disorders
#17
Sebastian Szmit, Wojciech Jurczak, Jan Maciej Zaucha, Monika Długosz-Danecka, Barbara Sosnowska-Pasiarska, Ewa Chmielowska, Monika Joks, Joanna Drozd-Sokołowska, Wanda Knopińska-Posłuszny, Wojciech Spychałowicz, Beata Kumiega, Grzegorz Charliński, Marta Morawska, Grzegorz Słomian
BACKGROUND: Algorithm of anthracycline-based chemotherapy with favourable cardio-oncological outcome should be clearly re-defined for lymphoma patients with significant pre-existing cardiovascular diseases. A clinical benefit of liposomal forms of anthracycline is still debatable. METHODS: Polish registry included observations of 138 lymphoma patients with concomitant cardiovascular disorders who received liposomal doxorubicin as cardioprotective alternative of conventional form...
May 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28152766/outcome-analysis-of-breast-cancer-patients-treated-with-cardiotoxic-agents-in-the-community-setting-a-single-institution-experience
#18
Munthir Mansour, Todd W Gress, Maria R B Tria Tirona
213 Background: Anthracyclines and anti-Her-2 targeted therapy are commonly used effective breast cancer treatments. They are known to decrease Left Ventricular Ejection Fraction (LVEF), which may increase patients' morbidity and mortality. There is currently no consensus on post treatment cardiac follow-up. Recent observations suggested that ACEI and B blocker drugs could have cardioprotective effects. We conducted a retrospective study to assess patients' cardiac outcome using post-treatment LVEF follow-up and effect of ACEI and B blocker on cardiac outcome for breast cancer patients who received cardiotoxic agents in our institution...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28029315/left-ventricular-dysfunction-with-trastuzumab-therapy-is-primary-prevention-the-best-option
#19
REVIEW
Paaladinesh Thavendiranathan, Eitan Amir
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
March 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27965861/exercise-to-prevent-anthrcycline-based-cardio-toxicity-exact-in-individuals-with-breast-or-hematological-cancers-a-feasibility-study-protocol
#20
Melanie R Keats, Scott A Grandy, Nicholas Giacomantonio, David MacDonald, Miroslaw Rajda, Tallal Younis
BACKGROUND: Anthracyclines (AC), widely used and effective anticancer agents, are known to induce both acute and chronic declines in cardiovascular health, ranging in severity from asymptomatic, subclinical dysfunction to substantial cardiomyopathy leading to congestive heart failure and death. There is substantial evidence that physical activity, higher levels of cardiorespiratory fitness, and exercise therapy can help prevent cardiovascular disease. Moreover, animal studies have shown that exercise performed concomitantly with AC treatment may attenuate early cardiac damage that results from AC exposure...
2016: Pilot and Feasibility Studies
keyword
keyword
98870
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"